TL;DR: Dysesthesia is an abnormal, often unpleasant skin sensation — tingling, prickling, burning, or heightened touch sensitivity. In retatrutide’s phase 3 program, it showed up more often at the 9 mg and 12 mg doses than with placebo, in both TRIUMPH-1 and TRIUMPH-4. The reported events skew mild-to-moderate and rarely caused people to stop treatment. What is genuinely unclear is why — the leading idea ties it to retatrutide’s third receptor, glucagon, which semaglutide and tirzepatide do not activate, but that remains a hypothesis, not an established mechanism.
Every incretin drug has its “known” side effects — nausea, reflux, constipation, the whole slowed-gut cluster covered in our guide to managing GLP-1 side effects. Retatrutide shares that cluster. But its phase 3 trials also logged something the earlier GLP-1 and GIP/GLP-1 drugs did not flag prominently: a skin-sensation signal, reported in the trial data as dysesthesia. This article lays out exactly what that word means, what the numbers say, and how much of the “why” is actually known.
What dysesthesia is, precisely
Dysesthesia and paresthesia get used interchangeably in casual conversation, but they are not the same thing, and the difference is the entire point of this article.
That distinction matters here because “dysesthesia” is the specific term the trial adverse-event coding used, not a looser catch-all for “weird tingling.” When trial investigators log dysesthesia rather than paresthesia, they are recording that participants described the sensation as bothersome, not merely odd.
What the retatrutide trials actually reported
Two phase 3 trials in the TRIUMPH program have reported dysesthesia data, with numbers that differ between them but point the same direction: more frequent at higher doses, and clearly more frequent than placebo.
In TRIUMPH-1 — the pivotal obesity trial — Eli Lilly’s own results release reported dysesthesia in 5.1% of participants on 4 mg, 12.3% on 9 mg, and 12.5% on 12 mg retatrutide, compared with 0.9% on placebo. In TRIUMPH-4 — the companion trial in participants with obesity and knee osteoarthritis — topline reporting put dysesthesia at 8.8% on 9 mg and 20.9% on 12 mg, against 0.7% on placebo. The two trials do not agree on an exact incidence, which is normal for adverse-event reporting across different populations and follow-up windows, but the shape is consistent in both: a low background rate on placebo, a clear step up at 9 mg, and a further step up at 12 mg.
Coverage of the trials also notes that this signal was not called out in retatrutide’s earlier phase 2 obesity trial — it emerged as the phase 3 program grew and diversified. That is worth sitting with rather than explaining away: a side effect that becomes visible with a larger sample size and different trial populations is what you’d expect for a genuine, if uncommon-to-moderate, drug effect, not a fluke of one study.
On severity and persistence, both trials describe the events as mostly mild-to-moderate, with reporting indicating the majority resolved during treatment and rarely drove discontinuation on their own. That last point is a meaningfully different story from the drug’s gastrointestinal effects, which are a more common reason people stop.
The broader tolerability picture: discontinuation by dose
Dysesthesia sits inside a larger, dose-dependent tolerability curve. In TRIUMPH-1, discontinuation due to any adverse event rose steadily with dose: about 4.1% at 4 mg, 6.9% at 9 mg, and 11.3% at 12 mg, compared with 4.9% on placebo. Notably, the 4 mg discontinuation rate was actually lower than placebo — a reminder that “dose-dependent” tolerability issues concentrate at the top of the ladder, not evenly across it.
Eli Lilly, TRIUMPH-1 phase 3 topline results, 2026. % of participants discontinuing for any adverse event, by assigned dose.
The most common adverse events driving that curve were the familiar incretin-class ones — nausea, diarrhea, constipation, and vomiting, all more frequent than placebo and rising with dose — the same mechanism-driven cluster covered in the GLP-1 side effects management guide and discussed for retatrutide specifically in our dosing and titration walkthrough. Dysesthesia is a smaller slice of that overall discontinuation curve, not the dominant driver of it — most people who stopped, stopped for GI reasons, not skin sensations.
Why retatrutide and not semaglutide or tirzepatide?
The detail that makes dysesthesia interesting rather than just another item on a side-effect list is which drug reports it. Semaglutide activates one receptor. Tirzepatide activates two. Retatrutide activates three — and the third one, glucagon, is unique to it among the major incretin-class drugs.
Semaglutide and tirzepatide trials have not reported a comparable dysesthesia signal at meaningful rates. Retatrutide’s phase 3 program has, twice, in two different trial populations. That pattern — a side effect showing up specifically in the drug with the extra glucagon-receptor arm — is the reason glucagon agonism is the leading hypothesis for what’s driving it. It is a hypothesis consistent with the data, not a conclusion the data has proven. Our comparison of retatrutide versus tirzepatide covers the receptor differences in more depth, and the topline TRIUMPH-1 efficacy numbers are broken down in our TRIUMPH-1 results overview.
What might explain it — and what does not, yet
Be clear-eyed here: no published mechanistic study has established why retatrutide produces dysesthesia. What exists are candidate explanations, each plausible, none confirmed.
- Glucagon-receptor signaling. Glucagon receptors are expressed outside the liver, including in some neural tissue, so chronic activation could plausibly influence peripheral nerve signaling in a way GLP-1-only or GLP-1/GIP drugs would not. This is the most-discussed hypothesis precisely because glucagon is retatrutide’s one distinguishing target — but “plausible given the receptor biology” is not the same as “demonstrated.”
- Rapid weight loss and micronutrient shifts. Retatrutide produces some of the largest weight-loss percentages reported for an incretin-class drug (covered in the what is retatrutide primer). Fast, large changes in body composition and intake can coincide with shifts in micronutrients that affect nerve function, independent of any direct drug action on nerves.
- Small-fiber sensory effects already present in metabolic disease. People with obesity and type 2 diabetes carry a higher baseline rate of small-fiber sensory changes before any intervention. A drug that changes metabolic state quickly could unmask or amplify sensations that were already present at a subclinical level.
None of these has been isolated as the cause in controlled research. It is entirely possible more than one contributes, or that the real explanation is something not yet on this list. The honest summary is: the signal is real and dose-dependent; the mechanism is not established.
Where this leaves things
The current evidence state, without overreaching in either direction: dysesthesia is a documented, dose-related adverse event in retatrutide’s phase 3 trials, absent (or at least not flagged) in the earlier phase 2 data, and it appears in two independent TRIUMPH trials with numbers that differ but point the same way. Events are mostly mild-to-moderate and rarely lead to stopping treatment. The mechanism is unresolved, and the glucagon-receptor hypothesis — while the most coherent explanation available — has not been tested directly. As the phase 3 program’s full peer-reviewed manuscripts and longer follow-up data become available, the picture on both incidence and cause should get sharper than what topline releases can currently offer.
Frequently asked questions
What does dysesthesia feel like?
Reported descriptions include tingling, prickling, burning, or a heightened, uncomfortable sensitivity to touch, sometimes to ordinary stimuli like clothing. The defining feature is that the sensation is unpleasant, which is what separates dysesthesia from the broader, sometimes neutral, category of paresthesia.
Is dysesthesia the same as paresthesia?
No. Paresthesia is any abnormal sensation, including ones that are simply odd but not bothersome, like the buzzing feeling of a foot “falling asleep.” Dysesthesia specifically describes an abnormal sensation that is unpleasant or distressing. Trial adverse-event coding used the term dysesthesia, meaning participants described it as bothersome rather than neutral.
How common is dysesthesia at retatrutide 12 mg?
Reported rates differ by trial: TRIUMPH-1 reported 12.5% at 12 mg versus 0.9% on placebo, while TRIUMPH-4 reported 20.9% at 12 mg versus 0.7% on placebo. Both trials agree on the pattern — clearly more frequent than placebo and higher at 12 mg than at lower doses — even though the exact numbers are not identical.
Does retatrutide-related dysesthesia cause people to stop treatment?
Reporting on both TRIUMPH-1 and TRIUMPH-4 describes dysesthesia events as mostly mild-to-moderate and says they rarely led to discontinuation on their own. Overall discontinuation for any adverse event did rise with dose in TRIUMPH-1 (4.1% at 4 mg to 11.3% at 12 mg versus 4.9% on placebo), but that curve is driven mainly by gastrointestinal events, not dysesthesia specifically.
Why don’t semaglutide and tirzepatide report this same side effect?
They have not reported a comparable dysesthesia signal at meaningful rates in their trials. The leading hypothesis is that retatrutide’s third receptor target, glucagon, which neither semaglutide (GLP-1 only) nor tirzepatide (GLP-1 and GIP) activates, plays some role. This is a hypothesis consistent with the pattern of which drug reports the effect, not a proven mechanism.
Was dysesthesia seen in retatrutide’s earlier phase 2 trial?
Coverage of the phase 2 obesity trial does not call out dysesthesia as a notable finding the way the phase 3 TRIUMPH trials do. It is not possible to say from public reporting whether this reflects a true absence at the phase 2 sample size or simply that it was not separately flagged; either way, the signal became visible as the phase 3 program expanded.
References
- Eli Lilly and Company. Lilly’s triple agonist retatrutide delivered powerful weight loss in the pivotal phase 3 TRIUMPH-1 obesity trial. Company press release, 2026.
- Eli Lilly and Company. Lilly’s triple agonist retatrutide delivered weight loss along with substantial relief from osteoarthritis pain in Phase 3 TRIUMPH-4 trial. Company press release, 2025.
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023;389(6):514-526.
- International Association for the Study of Pain (IASP). Terminology: Dysesthesia and Paresthesia definitions.
- Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism. 2022;34(9):1234-1247.